Background: Although lipids have been regarded as a passive component to constitute biomembranes, they can also play an important role in modulation of the activity or function of membrane-embedded proteins like receptors. Membrane lipids are presumed to be one of additional sites of action for receptor-acting drugs because their broad pharmacological spectra are not necessarily interpretable by the direct action on receptors. In order to obtain novel insights into the drug target and mechanism, we reviewed the membrane interactivity of different classes of drugs to act on representative receptors. Methods: A search of the scientific articles published between 1979 and 2018 was carried out by using PubMed/MEDLINE, Google Scholar and ACS Publications. The relevant research papers published in recognized international journals and on-line journals in English were preferred, but the review articles of specific importance were also included, although non-English language citations were excluded. Collected articles were reviewed by title, abstract and text for relevance with preference to more recent publications. Results: Results of the literature search indicate that membrane interactivity is shared by various drugs that act on α-and β-adrenergic, muscarinic and nicotinic acetylcholine, γ-aminobutyric acid type A, N-methyl-D-aspartate, opioid and transient receptor potential vanilloid type-1 receptors. These receptor agonists and antagonists not only interact with receptor proteins but also would structure-specifically interact with membrane lipids to affect receptors by modifying the lipid bilayer
INTRODUCTION
Receptors have a critical mechanistic contribution to a major class of drugs. In addition to the receptor agonistic and antagonistic activity, receptor-acting drugs exhibit different effects on seemingly unrelated membrane-associated proteins. The pharmacological mechanism(s) underlying them are not necessarily attributable to the direct action on receptors, suggesting the mechanistic interaction independent of receptor proteins. While many of receptor-acting drugs are amphiphilic, such structural characteristics are very likely to allow drug molecules to interact with lipid bilayers [1] . Lipids have been conventionally regarded as a passive component to constitute biomembranes but they can also modulate the activity or function of membraneembedded proteins: ion channels, enzymes and receptors [2] .
A number of drugs target receptors that are responsible for neurotransmission and neuronal functions. Besides the interaction with their relevant receptors, neurotransmitters can diffuse into synaptic membranes to modify their physicochemical properties, thereby shifting the conformational equilibrium of receptor proteins [3] . Considering the membrane effects of neurotransmitters, receptor-acting drugs would biophysically perturb membrane lipid bilayers as neurotransmitters do.
Membrane fluidity, membrane microviscosity (the reciprocal of membrane fluidity), membrane order and membrane elasticity influence the receptors diffusible in lipid bilayer membranes because such membrane properties are associated with the protein conformation optimal for the receptor activity [4] . The formation of ligand and receptor complexes depends on the affinity of ligands to receptors and the accessibility of ligands to receptor-binding sites, both of which are determined by the fluidity of biomembranes. Membrane fluidity, which refers to the relative motional freedom of the lipid components in lipid bilayers, is considered as one of determinants for the functions and dynamics of biomembranes and the conformational equilibria of membraneembedded proteins [1] . Membrane fluidity can affect the rotation and diffusion of drug molecules in lipid bilayer membranes, thereby modulating the activity and membrane location of drugs. The fluidity of intact membranes is determined by the composition of membrane lipids. Phospholipids with unsaturated acyl chains make membranes more fluid than ones with saturated acyl chains. With regard to characteristic lipids, sphingomyelin stiffens membranes and cholesterol bidirectionally regulates membrane fluidity to decrease or increase depending on experimental conditions. The interactions of drugs with liposomal and biological membranes are investigated by a variety of spectroscopic and biophysical methodologies including differential scanning calorimetry (DSC), electron spin resonance (ESR), nuclear magnetic resonance, X-ray diffraction and fluorescence anisotropy. Among them, fluorescence polarization has been most frequently used to determine drug-induced changes in membrane fluidity [5] . The polarization of fluorescence emitted by a membrane-incorporated fluorophore reflects its mobility in the surrounding membrane lipid bilayer environments. Fluorescence polarization is measured by excitation performed with monochromatic light that is vertically polarized, and the emission intensity detected through an analyzer oriented parallel or perpendicular to the direction of polarization of the excitation light by using different fluorophores such as 1,6-diphenyl-1,3,5-hexatriene (DPH), 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexa-triene (TMA-DPH) and N-phenyl-1-naphthylamine (PNA). These probes structureand lipophilicity-dependently penetrate into membranes to align with phospholipid acyl chains and locate in different membrane regions, indicating the fluidity of a membrane region specific to each individual probe. They are subject to the rotational restriction imparted by lipid bilayer rigidity or order. Drugs interact with lipid bilayers to produce more fluid or disordered membranes, which facilitate the probe rotation to emit the absorbed light in all directions, resulting in a decrease of fluorescence polarization. On the contrary, more rigid or ordered membranes produced by drugs disturb the probe rotation to emit the absorbed light in all directions, resulting in an increase of fluorescence polarization.
In order to obtain novel insights into the drug target and mechanism, we reviewed articles and information about the membrane interactivity of different classes of drugs (agonists and antagonists) that act on representative receptors: α-and β-adrenergic, muscarinic and nicotinic acetylcholine, γ-aminobutyric acid type A (GABA A ), N-methyl-D-aspartate (NMDA), opioid and transient receptor potential vanilloid type-1 (TRPV1) receptors.
METHODS
The present review is based on published articles and information retrieved from PubMed/MEDLINE, Google Scholar and ACS Publications. Databases were searched from 1979 to 2018. The papers published earlier than 1979 were exceptionally cited if they are essential to advancing the discussion. The research papers published in recognized international journals and on-line journals in English were preferred, but the review articles of specific importance were also included, although non-English language citations were excluded. Published abstracts were used when their complete articles were not available. The searches were carried out by using the following terms or combinations thereof: "membrane interaction", "membrane physicochemical property", "membrane fluidity", "adrenergic receptor", "acetylcholine receptor", "GABA A receptor", "NMDA receptor", "opioid receptor", "TRPV1 receptor", "agonist" and "antagonist". Collected articles were reviewed by title, abstract and text for relevance with preference to more recent publications. Their bibliographies were also searched for additional references.
RESULTS AND DISCUSSION
Results of the literature search indicate that different classes of receptor-acting drugs share the property to interact with membranes structure-specifically. Table 1 summarizes the representative membrane interactions of drugs, including relevant receptors and drugs' effects on membranes.
The membrane interactivity of drugs has been widely investigated using liposomal membranes or unilamellar vesicles. Even if drugs show relatively small changes in such protein-free lipid bilayers at their clinical concentrations, membrane-acting compounds are known to produce greater effects on natural membranes containing protein components.
Adrenergic Receptor-Acting Drugs
Adrenergic receptors are widely distributed in both the peripheral nervous system and the central nervous system. All of them are G protein-coupled receptors that are primarily classified into four basic subtypes: α 1 , α 2 , β 1 and β 2 . In the autonomic nervous system, α 1 -, β 1 -and β 2 -adrenergic receptors are localized in the postsynaptic terminals of sympathetic postganglionic neurons, whereas α 2 -adrenergic receptors are present in the presynaptic terminals of sympathetic postganglionic neurons.
Alpha-adrenergic receptor-acting drugs
While noradrenaline binds to α-and β-adrenergic receptors as a neurotransmitter, it exhibits a relatively strong agonistic effect on α 1 -and β 1 -adrenergic receptors. Therefore, noradrenaline is clinically usable as an injectable sympathomimetic drug for the treatment of critically low blood pressure. Burgess et al. [6] labelled plasma membranes isolated from rat liver with a fluorescent probe DPH and treated them with noradrenaline at 0.1-5 μM in the presence of 5 μM propranolol to block both β 1 -and β 2 -adrenergic receptors, followed by measuring DPH fluorescence polarization to determine the membrane interactivity. Noradrenaline interacted with the membranes to induce membrane fluidity-increasing effects, which were inhibited by non-selective α-adrenergic antagonist phentolamine and phenoxybenzamine at 1 μM and 50 μM, respectively. 
Beta-adrenergic receptor-acting drugs
Non-selective β-adrenergic agonist isoproterenol is one of drugs used for bradycardia and atrioventricular block. Hirata et al. [10] determined the physicochemical changes of rat reticulocyte membranes after treating with β-adrenergic drugs. Isoproterenol was found to enhance the membrane fluidity through an increase of phospholipid methylation with an EC 50 of about 30 μM. Its induced membrane fluidization was inhibited by non-selective β-adrenergic antagonist propranolol, but not by non-selective α-adrenergic antagonist phentolamine. It was also suggested that the enhancement of membrane fluidity by isoproterenol may promote the lateral movement of β-adrenergic receptors in the membranes.
Selective β 2 -adrenergic agonists such as indacaterol and salmeterol are effective in treating chronic obstructive pulmonary disease and persistent asthma. DPH fluorescence anisotropic experiments of Lombardi et al. [11] showed that salmeterol interacts with phospholipid liposomal membranes to increase their fluidity at concentrations above 1 μM. , β-blockers interacted with biomimetic membranes consisting of different phospholipids and cholesterol to increase their fluidity with the potency being propranolol > alprenolol > oxprenolol at 0.2-1 mM. By measuring fluorescence anisotropy of phosphatidylcholine unilamellar vesicles with DPH and TMA-DPH, Pereira-Leite et al. [16] revealed that propranolol induces larger increases of membrane fluidity than acebutolol at 10-250 μM. These comparative results indicate that non-selective β-blockers possess greater membrane interactivity than selective β 1 -blockers.
Beta-adrenergic receptor and membrane property
The activity of cardiac β-adrenergic receptors is determined by membrane physicochemical properties. In in vivo model experiments of Ma et al. [17] , cardiomyocyte plasma membranes prepared from cirrhotic rats showed a significant reduction of membrane fluidity, which was associated with a functional decrease of β-adrenergic receptors. Their following DPH fluorescence polarization study indicated that β-adrenergic receptor signaling is affected by the fluidity of cardiac plasma membranes [18].
Acetylcholine Receptor-Acting Drugs
Acetylcholine receptors are classified into muscarinic receptors (G protein-coupled) and nicotinic receptors (ionotropic). The former is peripherally localized in the postsynaptic terminals of parasympathetic postganglionic neurons, and the latter, in autonomic ganglia, neuromuscular junctions and adrenal medullae. 
Muscarinic
acetylcholine receptoracting drugs Muscarinic acetylcholine receptors are one of pharmacological targets for neurological diseases. Among muscarinic agonists, carbachol and pilocarpine are useful for glaucoma treatment, while oxotremorine experimentally induces tremor, ataxia and spasticity. Masturzo et al. [19] treated human lymphocytes, in which muscarinic acetylcholine receptors are possibly present, with oxotremorine or carbachol at 10 and 100 μM, and then measured fluorescence polarization with DPH. Consequently, both muscarinic agonists were found to decrease the membrane microviscosity.
Muscarinic acetylcholine receptor and membrane property
Muscarinic acetylcholine receptor binding is influenced by the fluidity change of rat frontal cortex membranes [22] .
Nicotinic acetylcholine receptor-acting drugs
Since pancuronium, vecuronium and atracurium competitively inhibit nicotinic acetylcholine receptors at the neuromuscular junction, these nicotinic antagonists are used as a muscle relaxant in general anesthesia and an aid to intubation. Aloui et al.
[23] incubated peripheral leukocytes obtained from human subjects with pancuronium for 30 min, and then measured fluorescence polarization after labelling the leukocyte membranes with TMA-DPH. Pancuronium increased the membrane fluidity at 0.01-1 mM in allergic patients and control subjects, while its membrane-fluidizing effects were more pronounced in the allergic groups.
Nicotinic acetylcholine receptor and membrane property
Studies to reconstitute the purified Torpedo californica receptors into defined lipid environments suggested that the functions of nicotinic acetylcholine receptors require the optimal fluidity of bulk membranes in addition to the membrane composition of cholesterol and negatively charged phospholipids [24,25].
GABA A Receptor-Acting Drugs
GABA A receptors are ligand-gated Cl -channels that are expressed in the central nervous system such as cortex, hippocampus and cerebellum. Inhibitory neurotransmitter GABA binds to GABA A receptors to allow the influx of Cl -into postsynaptic neurons, resulting in inhibition of neuronal excitability. Heteromeric GABA A receptors, which are composed of α and β subunits arranged around a central pore, have a specific binding site for GABA and different allosteric binding sites (distinct from the GABA recognition site) for general anesthetics and anesthetic adjuvants (propofol, barbiturates, benzodiazepines, volatile anesthetics, etc.) and also for plant components (thymol, menthol, other related terpenoids, etc.). These drugs and phytochemicals act as a positive allosteric modulator of GABA A receptors to induce anesthesia, sedation, anxiolysis and convulsion cessation.
Propofol
Given its high lipophilicity, propofol is very likely to penetrate into lipid bilayers and modify the fluidity of liposomal membranes [26] [27] [28] [29] and biological membranes [30] . Tsuchiya [26] compared the effects of propofol and its structurally-related compounds on dipalmitoylphosphatidylcholine liposomal membranes and biomimetic phospholipids plus cholesterol membranes by measuring fluorescence polarization with PNA, DPH and TMA-DPH. Of alkylphenolic derivatives, propofol most potently interacted with the membranes to increase their fluidity at 0.125-1.0 μM, which correspond to free propofol concentrations in blood during anesthesia. The structure-specific membrane interactivity of propofol is also evident when comparing between constitutional isomers of diisopropylphenol [29] . Propofol is able to interact with biomimetic membranes significantly at clinically relevant concentrations [26, 28] .
Barbiturates
Harris et al. [31] [32] [33] performed a series of studies to determine the effects of barbiturates on synaptic plasma membranes prepared from mouse brain by measuring fluorescence polarization. Pentobarbital and phenobarbital were confirmed to increase the membrane fluidity at sub-millimolar concentrations [33] . When comparing between DPH and TMA-DPH polarization changes, pentobarbital was more effective in fluidizing the membrane core than the membrane surface [32] . An ESR spectroscopic experiment of Houslay et al. [34] showed that phenobarbital increases the fluidity of liver plasma membranes isolated from rats at 4 mM by interacting with the external half of lipid bilayers. In TMA-DPH fluorescence polarization measurements of Aloui et al. [23] , thiopental increased the membrane fluidity of peripheral leukocytes obtained from human subjects at 0.1-1 mM and its membrane effects were greater in allergic patients than in non-allergic subjects.
Benzodiazepines
Mennini et al. [35] treated crude synaptic membranes isolated from rat hippocampus with diazepam and measured fluorescence polarization with DPH. They revealed that diazepam increases the membrane fluidity at concentrations ranging from 0.1 nM to 10 μM. Based on the in vitro results, they intraperitoneally injected rats with diazepam (10 mg kg -1 ), and then prepared brain synaptosomes 15 min after injection. Diazepam was found to increase the fluidity of hippocampal synaptic membranes, although such in vivo membranefluidizing effects were not significantly influenced by selective benzodiazepine receptor antagonist flumazenil (30 mg kg -1 , p.o.) given 1 min after diazepam injection. In DPH fluorescence polarization experiments of Kurishingal et al. [36] , chlordiazepoxide and diazepam interacted with egg-yolk phosphatidylcholine liposomal membranes to increase their fluidity at nanomolar concentrations.
Phytochemicals
Thymol from thyme (Thymus vulgaris, Lamiaceae) and menthol from peppermint (Mentha piperita, Lamiaceae) or spearmint (Mentha spicata, Lamiaceae) positively allosterically modulate GABA A receptors [37] [38] [39] . Several studies showed that thymol and menthol interact with lipid membranes to modify their physicochemical properties [9, [40] [41] [42] . Reiner et al. [40] compared the effects of GABAergic phenols on dipalmitoylphosphatidylcholine Langmuir films. Thymol, propofol and other structural analogs destabilized the lipid monolayers depending on lipophilicity. By 1 Hnuclear magnetic resonance spectroscopy, they revealed that thymol and propofol insert into phosphatidylcholine unilamellar vesicles and locate in the region between the choline polar group, the glycerol and the acyl chain first atom. In DPH fluorescence polarization experiments of Tsuchiya and Mizogami [42] , thymol, propofol and their related alkylphenols structurespecifically increased the fluidity of neuromimetic membranes prepared with phospholipids and cholesterol at 1-10 μM. Menthol also has the property to fluidize the similar neuro-mimetic membranes at 50 μM [9].
GABA A receptor and membrane property
Sooksawate and Simmonds [43] investigated the influence of membrane cholesterol on GABA A receptors in rat hippocampal neurons by a whole-cell patch clamp technique. Consequently, GABA effects were decreased by cholesterol enrichment that decreases the membrane fluidity and impedes the receptor protein conformational change, whereas increased by cholesterol depletion. By ligand binding assays with HEK293 and CHO cells expressing human GABA A α 1 β 2 γ 2S or α 5 β 2 γ 2S , Søgaard et al. [44] 
NMDA Receptor-acting Drugs
NMDA receptors are specific-type ionotropic receptors that are activated by neurotransmitter glutamate and glycine to open the ion channels nonselective to positively charged cations, resulting in neuronal excitation. Ketamine and its related drugs antagonize or inhibit NMDA receptor functions to produce dissociative anesthesia characterized by catalepsy, amnesia and analgesia. Ketamine is frequently used as an analgesic, sedative and anesthesia-maintaining agent because this non-competitive antagonist binds to the allosteric sites of NMDA receptors.
Ketamine
Mazzanti et al. [45] treated synaptic and mitochondrial membranes prepared from rat brains with 0-5 mM ketamine to determine its membrane effects by ESR spectroscopy using spin label 5-doxylstearate and 16-doxylstearate. Ketamine increased the membrane fluidity at concentrations as low as 0.25 mM. Based on the in vitro results, they intraperitoneally injected rats with ketamine (50 mg kg -1 ) to prepare brain synaptosomes, followed by ESR spectroscopic analysis with 5-doxylstearate. Ketamine showed in vivo effects to increase the fluidity of synaptic membranes after 30 min of anesthesia [46] . Lenaz et al. [47] carried out ESR spectroscopic experiments for different anesthetics and found the ability of ketamine to increase the fluidity of synaptic membranes from pig brains. DPH fluorescence polarization measurements of Tsuchiya and Mizogami [48] indicated that ketamine interacts with neuro-mimetic phospholipids plus cholesterol membranes to increase their fluidity at 50 μM.
Opioid Receptor-Acting Drugs
Morphine and its related drugs act on opioid receptors that are inhibitory G protein-coupled receptors with multiple subtypes of μ, κ and δ expressed in the neuronal circuits responsible for nociception. Their analgesic effects are induced through opioid receptor activation. In addition to opioid receptor proteins, membrane lipids have been suggested as one of possible acting sites for opioid analgesics and their antagonists.
Opiates
Hosein et al. [49] reported the in vivo effects of opioid receptor-acting drugs by injecting rats intraperitoneally with morphine (5, 10, 15 and 25 mg kg ) 15 min after morphine injection. They isolated crude brain mitochondrial lipids from drug-treated rats and dispersed the lipids in aqueous media to prepare lipid bilayers, followed by DSC analysis. Consequently, morphine was found to decrease the phase transition temperature of lipids, suggesting that it increases membrane fluidity. Naloxone completely reversed such membranefluidizing effects of morphine. By using brain lipid preparations from control rats (not treated with drugs), they demonstrated that morphine (50 nmol mg -1 lipid) exerts in vitro effects to decrease the phase transition temperature of lipids, which were reversed by naloxone (50 nmol mg -1 lipid). Heron et al. [50] verified the membrane interactivity of morphine by in vivo and in vitro experiments. They intraperitoneally injected rats with morphine (25 mg kg -1 ) or naloxone (2 mg kg -1 ), and then measured DPH fluorescence polarization of the membranes prepared from different brain regions 10-30 min after injection. Morphine induced a significant decrease in microviscosity of hippocampus and caudate membrane preparations, whereas naloxone increased the membrane microviscosity of both brain regions. Morphine also showed in vitro effects to increase the fluidity of rat brain membrane preparations at 0.01 and 10 μM, but the membrane-fluidizing effect of 10 nM morphine was reversed by 1 nM naloxone. Budai et al. [51] revealed that different morphine derivatives interact with dipalmitoylphosphatidylcholine liposomal membranes by DSC and electron paramagnetic resonance spectroscopic experiments. Of particular, codeine and N-methylcodeine significantly decreased the phase transition temperature of liposomes at 0.1 M.
Opioid receptor and membrane property

By [
3 H]D-Ala-enkephalinamide binding and DPH fluorescence polarization studies, Heron et al. [52] showed that the ligand binding to opioid receptors is reduced by increasing the fluidity of crude mitochondrial membranes isolated from mouse forebrains, whereas the ligand accessibility to opioid receptors is elevated by increasing the microviscosity of the membranes.
TRPV1 Receptor-Acting Drugs
Capsaicin acts on vanilloid or TRPV1 receptors that are expressed in primary afferent sensory neurons of the pain pathway [53] . Since TRPV1 receptors are the non-selective cation channels to modulate nociceptive and pain transmission, capsaicin concentration-dependently exerts analgesic and algesic effects. Capsaicin also opens TRPV1 channels to give Na + channel blockers like local anesthetics the access to cell interiors, promoting their transport to nociceptors.
Capsaicinoids
Meddings et al. [54] treated rabbit platelets, rat peritoneal mast cells and human erythrocytes with capsaicin at 40-320 µM, followed by measuring fluorescence polarization with DPH and TMA-DPH. Their results indicated that capsaicin specifically increases the fluidity of platelet membranes at all the tested concentrations, although it biphasically acts on mast cells and erythrocytes to rigidify their membranes at 320 µM but fluidize at lower concentrations. Tsuchiya [55] investigated the effects of capsaicin on biomimetic phosphatidylcholine plus cholesterol liposomal membranes by determining its induced changes in PNA, DPH and TMA-DPH fluorescence polarization. Capsaicin interacted with plateletmimetic and bacterial cell-mimetic membranes to show concentration-dependent biphasic effects to increase the membrane fluidity at 50 µM but decrease at 100-500 µM. Lundbaek et al. [56] reported that capsaicin alters phospholipid bilayer elasticity at 10-100 µM sufficiently to change the conformational preference of membrane-embedded proteins. As a background for such membrane interaction, Aranda et al. [57] speculated that capsaicin penetrates into phospholipid membranes with an alkyl chain aligned along the acyl chains and with hydroxyl and amide groups located closer to the lipid/water interface. By spectroscopically analyzing intrinsic fluorescence of capsaicin, Swain and Mishra [58] indicated the location of capsaicin in membrane phospholipid bilayers that a phenolic group is present near the head group region, while a hydrophobic tail, inside the core region.
Jensen et al. [59] compared the biophysical effects of structurally different amphiphiles on membrane lipid bilayers. Among them, capsaicin decreased the lipid bilayer stiffness. Kempaiah and Srinivasan [60] maintained hypercholesterolemic rats on diets containing 0.015% capsaicin for eight weeks, and then isolated erythrocytes for ESR spectroscopic and DPH fluorescence anisotropic measurements. They found that capsaicin increases the fluidity of erythrocyte membranes and also reverses the decreased membrane fluidity of hypercholesterolemic rats. Prakash and Srinivasan [61] reported in vivo membrane effects of capsaicin by the similar experiment, in which rats were maintained on 0.01% capsaicincontaining diets for eight weeks. Their DPH fluorescence polarization data indicated that capsaicin increases the fluidity of intestinal brush-border membranes.
Stereostructure-Specific Drug and Membrane Interaction
Unlike the interaction with functional proteins, the membrane interaction has a problem for the mechanism of drug action: whether drugs stereostructure-specifically interact with lipid bilayers to exert different effects between enantiomers. One enantiomer exhibits higher activity or toxicity than its enantiomeric counterpart and a racemic mixture. Enantioselectivity of receptor-acting drugs has been exclusively explained by their stereospecific affinity or binding to receptor proteins. Since two enantiomers absolutely differ in spatial configuration, they should differently behave in chiral matrices. Proteins are entirely made up of only L-amino acids, allowing drug stereoisomers to interact with receptor proteins enantioselectively. By contrast, the drug and membrane interaction has been conventionally recognized to equally affect membrane lipid bilayers. However, as Goldstein [62] described that the effects of drugs on membrane fluidity do not exclude some specificity, membrane lipids potentially contribute to the stereostructurespecific interaction with drugs.
Alpha 2 -adrenergic agonist medetomidine interacts with neuro-mimetic membrane consisting of phospholipids and cholesterol with the potency being dexmedetomidine (Dmedetomidine) > racemic medetomidine > levomedetomidine (L-medetomidine) at 50 μM for each [9] . Of β-adrenergic antagonists, R(+)-propranolol most potently increases the fluidity of cholesterol-containing membranes at 50 μM, followed by racemic propranolol and S(-)-propranolol in the decreasing order of membrane interactivity [9] . Menthol, a positive allosteric modulator of GABA A receptors, interacts with neuro-mimetic membranes containing cholesterol to increase their fluidity with the potency being (+)-menthol > (-)-menthol at 50 μM for each [9] . Zunino et al. [63] compared the membrane interactivity of neomenthol stereoisomers, which have the GABA A receptor-modulatory activity to enhance the currents induced by low concentration GABA [64] . Their DPH fluorescence anisotropic experiments revealed that (+)-neomenthol increases the membrane fluidity of dipalmitoylphosphatidylcholine unilamellar vesicles at 0.3-1.8 mM more significantly than (-)-neomenthol. NMDA receptor-acting ketamine interacts with neuromimetic phospholipids plus cholesterol membranes to increase the membrane fluidity with the potency being S(+)-ketamine > racemic ketamine at 50 μM for each [9, 48] . Hosein et al. [49] intraperitoneally injected rats with levorphanol (5 mg kg -1 ) or dextrorphan (5 mg kg -1 ). In their following DSC study, levorphanol increased the fluidity of membrane preparations from crude rat brain mitochondrial lipids as well as morphine (15 mg kg -1 , i.p.), whereas its pharmacologically inactive enantiomer dextrorphan showed no significant membrane effects.
Biological membranes play an important role not only as the matrix to hold receptor proteins but also in the process to discriminate drug molecules. Cellular and plasma membranes structurally consist of lipid bilayers of phospholipids and cholesterol. Such lipid components potentially mediate the enantioselective action of drugs because they have chiral centers. Phospholipids interact preferentially with molecules of the same chirality, producing higher selectivity for one enantiomer than its enantiomeric counterpart [65] . Cholesterol with more chiral carbons than phospholipids is more likely to impart chirality to lipid bilayers and its absolute configuration would influence the membrane physicochemical property [66] . Drugs are considered to interact with chiral lipid membranes to induce membrane fluidity changes that are discriminable between enantiomers.
The composition of membrane lipids, which modulate the function and location of proteins in biomembranes, varies according to cell and tissue types [67, 68] . Such variations would make the drug and membrane interaction characteristic to neuronal, cardiovascular and other cells. The effects of membrane-acting drugs remarkably differ by membrane lipid components and their compositions [5] , possibly enhancing the membrane interaction specificity for cells.
Receptors and Lipid Raft Microdomains
The conventional concept "membranes consisting of uniformly distributed lipids" has been substantially modified by the recent theory that a microdomain biophysically differing from bulk membranes is present in biological membranes. The most intensively studied membrane microdomain is lipid rafts, the highly ordered membrane compartments enriched in cholesterol, sphingolipids and characteristic proteins. Lipid rafts float in the liquid-disordered lipid bilayers to play a role of the platform for functional proteins. Since lipid rafts influence the fluidity of membrane compartments and regulate the neurotransmission and receptor trafficking, they are responsible for a variety of cell membrane-related physiological process and pathogenesis. Another type of membrane microdomain is caveolae that are regarded as a special group of rafts to contain peculiar protein caveolins. The localization in lipid raft microdomains and the functional regulation by lipid rafts are known for α 1 -adrenergic receptor [69] , β 2 -adrenergic receptor [70] , muscarinic acetylcholine receptor [71] , nicotinic acetylcholine receptor [72] , GABA A receptor [73], NMDA receptor [74] , opioid receptor [75] and TRPV1 receptor [76] . Lipid rafts potentially modify the receptor affinity to ligands and the integrity of lipid rafts modulates the effects of agonists on their relevant receptors [77, 78] .
Several drugs and compounds act on receptorlocalizing lipid rafts to cause their physicochemical modification [79] . The drugs to induce a significant increase in membrane fluidity are likely to affect the ordered membrane compartments more effectively than membraneinactive ones. Membrane fluidity-modifiers also show raft-making or raft-breaking effects depending on their located region in lipid bilayers [80] . The interactivity with lipid bilayers may be associated with the selectivity of drugs for receptor subtypes that are activated by the same ligands but are differently localized in lipid rafts. For example, β 2 -adrenergic receptors are concentrated in lipid rafts, while controversy remains for β 1 -adrenergic receptors [81] . The localization in caveolae/lipid rafts is prerequisite to β 2 -adrenergic receptors in cardiac myocytes for physiological signaling, but not to β 1 -adrenergic receptors [70] . Non-selective β-adrenergic antagonists interact with lipid raft model membranes to change their fluidity, although selective β 1 -adrenergic antagonists are not membrane-active [14] [15] [16] . Therefore, nonselective β-blockers would inhibit the activity of β 2 -receptors by interacting with lipid rafts together with acting on β 1 -receptor proteins antagonistically, whereas selective β 1 -blockers could affect the activity of β 1 -receptors through the specific action on β 1 -receptor proteins but not the activity of β 2 -receptors through the interaction with lipid rafts.
CONCLUSION
Lipids are no longer only a structural component to constitute biomembranes but a critical factor to modulate the location and activity of membrane proteins as well as define membrane microdomains. Since integral membrane proteins are not rigid entities, the modification of membrane fluidity would influence the functions of proteins embedded in membrane lipid bilayers. In addition to acting on receptors directly, drugs are considered to interact with membranes to affect their relevant receptors by changing the lipid bilayer environments surrounding them. The structure-specific membrane interaction is pharmacologically contributable to diverse effects of receptor-acting drugs. Not all receptor-acting drugs interact with membrane lipids and not all membrane-interacting drugs act on receptor proteins. However, the membrane interactivity may be useful as a tool for screening lead compounds in drug discovery, while biophysical and biochemical studies on the interactions of drugs with lipid bilayers were conventionally of pharmacokinetic interest for drug design.
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